Dr. GPCR Summit 2021
Live Talk Schedule
GPCRdb Resources
Dr. David Gloriam, Dr. Albert Kooistra, Gaspar Pandy-Szekeres
September 13, 2021 at 2:00:00 PM
CXCR4 heteromers as novel cancer targets
Juan José Fung, Ph.D., Pina Cardarelli, Ph.D.,
September 13, 2021 at 5:00:00 PM
Unconventional GPCR Signaling in the Hedgehog Pathway
Dr. Ben Myers
September 13, 2021 at 6:00:00 PM
The Phosphorylation Barcode as a Mechanism of Biased β-arrestin 2 Recruitment and Conformation at CXCR3
Dylan S. Eiger
September 13, 2021 at 7:00:00 PM
A distinct activation mechanism in GPCR dimers: Insights from cryo-EM snapshots of the entire Class D1 GPCR activation pathway
Vaithish Velazhahan
September 13, 2021 at 8:00:00 PM
Heat Shock Protein 90 is a Novel Opioid Receptor Signaling Regulator that can be Targeted to Improve Opioid Therapy
Dr. John Streicher
September 13, 2021 at 9:00:00 PM
Through the Looking-Glass: Structure-Based Drug Discovery across the GPCRome
Dr. Chris de Graaf
September 14, 2021 at 12:00:00 PM
Designer G protein-coupled receptors as tools to identify novel targets for antidiabetic and anti-obesity drugs
Jürgen Wess
September 14, 2021 at 1:00:00 PM
"Toolboxing" solid-state NMR spectroscopy for GPCR studies
Dr. Jiafei Mao
September 14, 2021 at 2:00:00 PM
GPCRomics: Identifying novel GPCR targets in health and disease
Paul A. Insel
September 14, 2021 at 3:00:00 PM
A Funny Thing Happened at the Dr. GPCR Summit
Dr. Robert Lefkowitz, Dr. Randy Hall
September 14, 2021 at 5:00:00 PM
Twist Biopharma: Synthetic DNA Technologies Enable Fast and Responsive anti-GPCR Antibody Discovery and Optimization
Dr. Aaron K. Sato
September 14, 2021 at 7:00:00 PM
Advancing GPCR drug discovery with bioSensAll® platform technology
Dr. Meriem Semache
September 15, 2021 at 2:00:00 PM
GPCR activation mechanisms across classes and macro/micro scales
Dr. David Gloriam
September 15, 2021 at 6:00:00 PM
Hydroxycarboxylic acid receptor 3 and GPR84 signaling with potential implications for immune cell function
Claudia Stäubert
September 15, 2021 at 7:00:00 PM
Engineering a human GPCR to create self-tunable engineered yeast probiotics for the treatment of inflammatory bowel disease
Benjamin M. Scott
September 15, 2021 at 8:00:00 PM
The challenges of targeting RXFP1, the receptor for the heart failure drug candidate relaxin, with peptide mimetics and small molecules
Ross AD Bathgate
September 15, 2021 at 9:00:00 PM